Recipharm AB - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.
This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.
Oct 25, 2022: Recipharm bolsters blow-fill-seal capabilities with Lab+
Oct 19, 2022: Recipharm strengthens pre-filled syringe and cartridge offering with new investment
Jul 14, 2022: Transpire Bio announces agreement with Recipharm for the development of an inhaled medicine
This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.
Scope
- Business description - A detailed description of the company’s operations and business divisions.
- Corporate strategy - The publisher's summarization of the company’s business strategy.
- SWOT analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history - Progression of key events associated with the company.
- Major products and services - A list of major products, services and brands of the company.
- Key competitors - A list of key competitors to the company.
- Key employees - A list of the key executives of the company.
- Executive biographies - A brief summary of the executives’ employment history.
- Key operational heads - A list of personnel heading key departments/functions.
- Important locations and subsidiaries - A list of key locations and subsidiaries of the company, including contact details.
Highlights
Recipharm AB (Recipharm) is a contract development and manufacturing organization (CDMO) that offers manufacturing, development, and technology services. The company's manufacturing services include contract manufacturing of pharmaceuticals such as semi-solids, oral liquids, solid doses, and sterile products, besides clinical trial materials including APIs and other drugs. Recipharm’s development and technology services assist customers from the initial product concept to the approved commercial pharmaceutical drug. It includes services such as raw material supply, formulation, and validated analytical methods, among others. The company operates in the UK, Germany, Spain, Italy, Sweden, France, Portugal, India, Israel, and the US. Recipharm is headquartered in Stockholm, Sweden.Recipharm AB Key Recent Developments
Nov 30, 2022: Recipharm invests in its single dose nasal platform capabilitiesOct 25, 2022: Recipharm bolsters blow-fill-seal capabilities with Lab+
Oct 19, 2022: Recipharm strengthens pre-filled syringe and cartridge offering with new investment
Jul 14, 2022: Transpire Bio announces agreement with Recipharm for the development of an inhaled medicine
Reasons to Buy
- Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
- Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
- Understand and respond to your competitors’ business structure and strategies with the publisher's detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
- Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.
Table of Contents
Section 1 - About the Company- Recipharm AB - Key Facts
- Recipharm AB - Key Employees
- Recipharm AB - Key Employee Biographies
- Recipharm AB - Major Products and Services
- Recipharm AB - History
- Recipharm AB - Company Statement
- Recipharm AB - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Company Overview
- Recipharm AB - Business Description
- Recipharm AB - Corporate Strategy
- Recipharm AB - SWOT Analysis
- SWOT Analysis - Overview
- Recipharm AB - Strengths
- Recipharm AB - Weaknesses
- Recipharm AB - Opportunities
- Recipharm AB - Threats
- Recipharm AB - Key Competitors
- Recipharm AB, Pharmaceuticals & Healthcare, Deals By Year, 2016 to YTD 2022
- Recipharm AB, Pharmaceuticals & Healthcare, Deals By Type, 2016 to YTD 2022
- Recipharm AB, Recent Deals Summary
- Nov 30, 2022: Recipharm invests in its single dose nasal platform capabilities
- Oct 25, 2022: Recipharm bolsters blow-fill-seal capabilities with Lab+
- Oct 19, 2022: Recipharm strengthens pre-filled syringe and cartridge offering with new investment
- Jul 14, 2022: Transpire Bio announces agreement with Recipharm for the development of an inhaled medicine
- Apr 29, 2022: Recipharm offers services to enable switch to next generation pMDI propellants
- Feb 23, 2022: Recipharm invests in new high-speed filling line to meet demand for aseptic products
- Jan 28, 2022: Recipharm: Construction works launch at new fill finish facility in Morocco
- Jan 27, 2022: Recipharm secures vaccine manufacturing deal
- Sep 24, 2021: First customer boards Recipharm's soft mist inhaler technology platform
- Aug 24, 2021: Recipharm launches new laboratory to expand analytical services offering
- Methodology
- About the Publisher
- Contact the Publisher
- Disclaimer
- Recipharm AB, Key Facts
- Recipharm AB, Key Employees
- Recipharm AB, Key Employee Biographies
- Recipharm AB, Major Products and Services
- Recipharm AB, History
- Recipharm AB, Other Locations
- Recipharm AB, Subsidiaries
- Recipharm AB, Key Competitors
- Recipharm AB, Pharmaceuticals & Healthcare, Deals By Year, 2016 to YTD 2022
- Recipharm AB, Pharmaceuticals & Healthcare, Deals By Type, 2016 to YTD 2022
- Recipharm AB, Recent Deals Summary
- Recipharm AB, Pharmaceuticals & Healthcare, Deals By Year, 2016 to YTD 2022
- Recipharm AB, Pharmaceuticals & Healthcare, Deals by Type, 2016 to YTD 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Boehringer Ingelheim International GmbH
- Iconovo AB
- Fareva SA
- Iconovo AB
- Catalent Inc
- Fareva SA
- F. Hoffmann-La Roche Ltd
- Corden Pharma International GmbH
- Boehringer Ingelheim International GmbH
- Patheon NV
- Vetter Pharma-Fertigung GmbH & Co KG
- Catalent Inc
- Corden Pharma International GmbH
- Vetter Pharma-Fertigung GmbH & Co KG
- Patheon NV
- F. Hoffmann-La Roche Ltd
